Cargando…
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
Pulmonary function is impaired in untreated mucopolysaccharidosis type VI (MPS VI). Pulmonary function was studied in patients during long-term enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB; rhN-acetylgalactosamine 4-sulfatase). Pulmonary function tests prior to and...
Autores principales: | Harmatz, Paul, Yu, Zi-Fan, Giugliani, Roberto, Schwartz, Ida Vanessa D., Guffon, Nathalie, Teles, Elisa Leão, Miranda, M. Clara Sá, Wraith, J. Edmond, Beck, Michael, Arash, Laila, Scarpa, Maurizio, Ketteridge, David, Hopwood, John J., Plecko, Barbara, Steiner, Robert, Whitley, Chester B, Kaplan, Paige, Swiedler, Stuart J., Hardy, Karen, Berger, Kenneth I., Decker, Celeste |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828556/ https://www.ncbi.nlm.nih.gov/pubmed/20140523 http://dx.doi.org/10.1007/s10545-009-9007-8 |
Ejemplares similares
-
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012) -
Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
por: Shams, Sedigheh, et al.
Publicado: (2017) -
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013) -
Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2017) -
Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)